Objective Few treatment options are available for advanced non-small cell lung cancer
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …

Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

Purpose: Gefitinib plays an important role in non‐small‐cell lung cancer (NSCLC) treatment;
however, progression of the disease occurs in most patients even after an initial response …

BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Methods: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib
failure at Seoul National University Hospital between August 2005 and November 2011 …

Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …

Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …

Background: The optimal treatment for patients with progressive non-small cell lung cancer
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …